Covance is latest CRO to cut 2009 forecast on lower Q1 demand
New Jersey, US based Covance is the latest CRO to cut earnings projections and blame falling pharmaceutical industry demand for its woes.
Archives for April 29, 2009
Optimising business key for pharma in downturn, says CourtSquareGroup
US strategic consultants CourtSquareGroup say that while optimisation of operations is key for the drug industry, companies risk losing the business knowledge required to undertake such action in the scramble to cut costs in the global downturn.
Pfizer eyes FOBs and small to midsized deals
Pfizer is monitoring opportunities in follow-on biologics and continuing to look for small to mid-sized deals as it plans for life without Lipitor, global revenues of which fell by 13 per cent in Q1.
Encorium Group signs $2m in new contracts, results indicate tough market
US contract research organisation (CRO) Encorium has reported $2m in new and repeat business deals on the same day it posted gloomy Q4 figures and cited the "drop in demand" refrain heard across the trial sector.
Lilly & Amylin team up to create diabetes pen
Eli Lilly and Amylin Pharmaceuticals are jointly developing an exenatide once weekly pen device, which should provide a more convenient way for diabetics to treat themselves.
Phase Forward prospers despite clients’ difficulties
Clinical trial software provider Phase Forward posted strong Q1 financial results, with CRO related revenues jumping by 52 per cent despite the difficulties facing companies in the sector.